Announced
Completed
Financials
Sources
Tags
Friendly
Venture Capital
Acquisition
Single Bidder
Completed
Minority
Biotechnology
biotechnology
Germany
Private Equity
Cross Border
Private
Synopsis
Fidelity Management & Research Company led a $110m Series B round in T-knife Therapeutics, a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, with participation from LSP, Qatar Investment Authority, Casdin Capital, Sixty Degree Capital, CaaS Capital, RA Capital Management, Versant Ventures and Andera Partners. The company plans to use proceeds from the financing to expand its scientific team, increase manufacturing capacity and advance its pipeline of T-cell receptor engineered T cell therapies.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.